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The Inflammatory Bowel Diseases (IBDs) are diagnosed more commonly in children and
adolescents. Following diagnosis, the key objectives are to achieve and then maintain
remission. Although some therapies are able to effectively modify and modulate inflam-
matory events, none of the available interventions cure these conditions. Consequently,
children and their parents face uncertainty and may look to alternative management options
as ways to help their child, which may include various complementary and alternative med-
icines (CAMs). A number of studies have shown that many children with IBD receive or are
given CAM agents.This article reviews the rates and patterns of CAM use in children with
IBD, and emphasizes the increasing importance of these aspects of the management of
children with IBD.
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INTRODUCTION
The term complementary and alternative medicine (CAM) can
be defined as “a group of diverse medical and healthcare sys-
tems, practices, or products that are not generally considered
part of conventional medicine” (1). CAMs encompass a wide
range of therapies, including nutritional supplements, medi-
tation, and herbal remedies (2, 3). Several of these agents,
such as probiotics, may have specific beneficial effects upon
the gastrointestinal (GI) tract, including modulation of host-
pathogen interactions and anti-inflammatory benefits. Other
CAM interventions may improve the individual’s general well-
being or enhance the person’s abilities to cope with stressful
events.
Such potential benefits may be especially relevant for an indi-
vidual suffering a chronic illness. Rates of use of CAM agents
tend to be higher in individuals with chronic, debilitating, or life
threatening illnesses. In one study, for instance, three times as many
children with Inflammatory Bowel Disease (IBD) or cerebral palsy
were using CAM than healthy children (4). The IBDs are chronic
incurable conditions affecting the GI tract, leading to numerous
bowel symptoms as well as systemic consequences (5). This article
will review available data of the patterns of CAM use in children
with IBD.
CROHNS AND COLITIS
THE INFLAMMATORY BOWEL DISEASES
Crohn’s disease (CD) and ulcerative colitis (UC) are the two
main types of IBD (5, 6). Although these two conditions can
be differentiated on the basis of disease location, inflammatory
patterns, and specific histological findings, these diseases also
have many common features. In particular, they both feature
chronic inflammation of the GI tract, lead to an array of
intestinal symptoms (such as diarrhea and pain), and both are
incurable.
Although the precise causes of IBD are yet fully understood, it
is commonly accepted that IBD occurs as a result of interactions
between the intestinal mucosa and the intestinal microflora or
their byproducts, leading to dysregulated inflammation in a genet-
ically susceptible host. In recent years rates of IBD have increased
in many countries, including in areas where IBD was previously
seen rarely (7, 8).
Both CD and UC can begin at any age, with around a quarter of
individuals diagnosed in childhood (9). Recent data show tenfold
increases in UC and CD over a decade in one Australian tertiary
center (10, 11).
Published series consistently show that childhood-onset CD
and UC differ substantially from the disease presenting in adults
(12, 13). Most children diagnosed with UC have pan-colonic
involvement at diagnosis with isolated distal changes being
uncommon. Children diagnosed with CD tend to have much more
extensive disease than adults: pan-enteric disease, especially with
upper GI tract involvement, occurs commonly (12).
CONSEQUENCES OF IBD IN CHILDREN
Crohn’s disease and UC commonly impact adversely upon growth,
pubertal development, and daily activities in children. Almost all
children with CD, and up to two-thirds of those with UC, have
lost weight or grown poorly prior to diagnosis (14). Many chil-
dren will have impaired linear growth and some will have delayed
pubertal development at diagnosis. Furthermore, a large number
of children will have ongoing problems with growth, and pubertal
development following diagnosis (15).
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Growth disruption is consequent partly to impaired dietary
intake, but especially to uncontrolled inflammation. The
pro-inflammatory cytokine, interleukin (IL)-6 impairs synthesis
and activity of insulin-like growth factor (IGF)-1, a key signaling
component of the growth hormone pathway (16). In addition,
IL-6 and tumor-necrosis-factor (TNF)-α also have direct adverse
effects upon growth plate function.
In addition, CD and UC commonly adversely affect the day to
day functioning of children or adolescents with these conditions
(17). Children may have difficulty playing sports or have inter-
rupted school attendance. Further, depression and anxiety occur
at higher rates. These aspects contribute to impaired health related
quality of life (QOL) (18).
MANAGEMENT OF PEDIATRIC IBD
Whilst the central goals of the management of IBD in children
and adolescents are to improve symptoms and resolve inflamma-
tion, further objectives include ensuring that children have normal
growth and development, and that they are able to undertake
regular day to day activities (5). Current standard medical thera-
pies can be divided into those that are used to induce remission
and others used to maintain remission. Examples of the former
include exclusive enteral nutrition, corticosteroids, and biological
therapies (e.g., infliximab). Interventions utilized for maintenance
of remission include aminosalicylates, immunosuppressive drugs
(e.g., azathioprine), and biological therapies (5). However, none of
the available therapies for pediatric CD are curative. In addition,
almost all therapies have potential side-effects. Hence, the benefits
of any specific therapy need to be weighed against the potential
adverse effects of this intervention within the individual patient
context.
Almost all children and adolescents will commence a therapy
following diagnosis and will have ongoing therapies throughout
childhood. Many children will take a number of medicines one or
more times each and every day. Despite these interventions, these
children remain at risk of relapse of disease,which may be triggered
by stressful events or following an inter-current infection.
Because of the persistent and pervasive features of CD and UC
in childhood, and in the context of no curable intervention, the
parents of many children consider other options, including CAM.
The use of CAM therapies, the range of available agents and con-
tributory factors have been evaluated in a number of studies over
the last decade.
CAM THERAPIES CONSIDERED FOR IBD
A range of CAM therapies have been considered in the con-
text of IBD. Some of these may have particular relevance for
individuals with IBD (3). Some CAM therapies have direct anti-
inflammatory effects that could enhance disease control in con-
junction with standard treatments. These include nutritional
interventions, agents that may enhance host immune responses,
and interventions that may modulate psychological or emotional
responses to the disease. Herbal therapies appear to be one of
the most commonly used CAM, but substantial variations occur
between cultures and regions of the world.
Langmead and Rampton (3) reviewed the data supporting
the benefits of CAM therapies used commonly in the context of
IBD. These authors concluded that there is little controlled data
supporting agents that have been commonly suggested for IBD.
Note was made, however, of promising data arising from studies
examining acupuncture in IBD. Hilsden et al. (19) made simi-
lar conclusions relating to the evidence supporting CAM in IBD
and referred to specific resources, including internet databases of
available CAM agents.
USE OF CAM IN ADULTS WITH IBD
The use of CAM in adults with IBD was reviewed recently, with
focus upon reports that included 100 or more adult subjects with
IBD (19). Current use of CAM across these studies ranged from
11 to 34%, with up to 60% having either past or current use.
The authors identified a range of factors for the use of CAM:
these were dependent upon the situation and methodology used
to collect data. Overall, however, common factors include dis-
ease severity and duration, requirements for standard medications,
QOL, and history of surgical intervention and requirement for
hospitalization.
One earlier individual study has illustrated variations in the
rates and patterns of CAM usage in adults with IBD between coun-
tries (20). This study was conducted late last century and used
a self-administered questionnaire to assess usage in 218 adults
with IBD from two North American centers and two centers in
Europe. Rates of CAM use varied between 31 and 68% of subjects,
with substantially higher rates seen in North American patients.
The respondents in this series most commonly used exercise,
prayer, counseling, massage, chiropractic, and relaxation thera-
pies. Respondents reported that the factors supporting their use
of CAM included dissatisfaction with standard therapies, unfa-
vorable attitude to healthcare facilities, and sense of hopelessness
about their medical condition.
USE OF CAM IN CHILDREN AND ADOLESCENTS WITH IBD
A number of studies have examined the use of CAM by children
and adolescents with IBD. Although patterns have been observed,
there are also some specific regional and/or cultural variations.
Further, there are some particular differences from the patterns of
CAM usage seen in adults with IBD.
In general, the decision to administer CAM therapies to chil-
dren and adolescents will likely be made by a parent or caregiver,
rather than the child themselves. Consequently, the decision mak-
ing process may reflect parental attitudes along with perceived
requirements and responses.
We examined CAM usage in Australian children attending gen-
eral gastroenterology clinics (21, 22) and attending specific IBD
clinics (23) using a specific questionnaire. In an initial study of 92
children attending a range of gastroenterology clinics, more than
one third of the children were being given CAM (21). Just 10 of
this group had been diagnosed with IBD: three of these children
were taking CAM. Overall, 90% of the parents of the 92 children
reported that they would consider a CAM agent for their child if
recommended.
A subsequent report a decade later involved 98 children attend-
ing general gastroenterology clinics in the same hospital (22).
The children in this cohort were being managed for a variety of
GI conditions, but none were diagnosed with IBD. This report
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demonstrated increased recent or current usage rates (69%) com-
pared to the previous estimates, with wide awareness and accep-
tance by parents. Nutritional supplements and probiotics were the
most commonly used CAM, followed by herbal remedies, massage,
fish oil, and relaxation techniques.
In addition, a further questionnaire-based assessment solely of
children diagnosed with IBD was conducted in the same hospital
(23). This report involved the responses from 46 families follow-
ing receipt of a mailed questionnaire. Almost three quarters of
the children were reported by their parents to be receiving CAM,
which was greater than the rate of the children without IBD from
the same location. On average these children were receiving 2.4
CAM agents, with four children having five or more therapies.
Fish oil and probiotics were the most common agents utilized
in these children. Other common interventions included herbal
remedies, homeopathy, and supplementary vitamins. Relaxation
techniques, massage, and chiropractic interventions were uncom-
monly utilized. Interestingly only 12% of the CAM-users reported
the agents to be very effective – however 50% of the users also
noted partial benefits. In this cohort, there were no associations
between age, gender, disease type or duration of disease, and CAM
usage.
In contrast to the high rates seen in this Australian group, much
lower rates were seen in a Canadian cohort (24). Twenty-two per-
cent of this group reported having ever used CAM, whilst just
6.7% reported current use. Other European and North American
reports have defined rates between these extremes.
Heuschkel et al. (25) surveyed 208 children seen in two North
American centers and one center in the United Kingdom. CAM
usage was reported in 41%, with megavitamins, diet supplements,
and herbal remedies being most commonly administered. Higher
rates of CAM usage were seen in children whose parents also use
CAM and those who had more side-effects secondary to stan-
dard drugs. Interestingly, 59% of non-users reported an interest
in learning more about CAM.
A similar rate of CAM usage was determined in a large cohort
of 334 children recruited from one city in the USA (26). Although
megavitamins were used commonly, nutritional supplements,pro-
biotics, and fish oil were also frequently reported. The factors
associated with use of CAM were explored in more detail in this
study. Univariate analysis suggested that CD, access to the internet,
poor QOL, and more frequent school absences were factors favor-
ing the use of CAM. Further regression analysis ascertained that
poor QOL, use of the internet for research about IBD, and a need
for calorie supplementation were specific factors linked with CAM
use. In addition, those individuals requiring surgical procedures
had lower rates of CAM use than those who the subjects who did
not undergo surgery.
A different set of factors was illustrated in a report of the use
of CAM in 86 Scottish children (27). A higher number of corti-
costeroid courses, higher parental education, and lower patient
age were identified as the key factors for the use of CAM in
these children. Around two-thirds of the group had used, and
37% were currently using CAM. The most common agents in
this setting were probiotics and diary-free diet. Overall, vitamin
supplements, herbal remedies, and homeopathy were used less fre-
quently in these children than in the cohorts from North America.
Interestingly, however, 89% of the parents in this group reported
that they would consider giving CAM in the future.
Probiotics were again reported as the most commonly utilized
agent in another North American study involving 236 youngsters
with IBD (28). This study recruited children with IBD and chil-
dren with other chronic disease states. Half of the children with
IBD included in this study used CAM, which was greater than
rates seen in children with other chronic disease states. Educational
achievement, general well-being, European background, and a his-
tory of more side-effects from standard drugs were factors linked
with CAM use in this group.
One further study specifically ascertained the use of mind-body
CAM interventions (yoga, prayer, guided imagery, relaxation, or
meditation) in children with IBD (29). Almost two-thirds of the
67 adolescents included in this assessment used prayer for symp-
tom management more than once every week. Relaxation and
imagery were more commonly used than meditation or yoga. The
girls in this group were more likely to use relaxation techniques
regularly, whilst the children with more severe disease would be
more likely to consider future use of relaxation than those with less
severe activity. There was little relationship between QOL scores
(using a generic tool) and use of CAM. Similar to the other pedi-
atric cohorts, the adolescents in this group reported high rates of
potential future use of all five types of mind-body CAM.
One important aspect of the use of CAM therapies is clear
communication about the use of these agents. It is important for
practitioners to be able to introduce the concept of CAM usage
within the therapeutic relationship, and also for practitioners to
remember to ask about possible usage. Furthermore, if asked about
a CAM agent by a patient or parent, then the practitioner should
endeavor to answer with an open and non-dismissive approach, in
order to maintain clear lines of communication. One New Zealand
study ascertained that only 11% of patients could recall having
been asked by a doctor if they were using CAM (30). Further,
almost one quarter of the patients in our recent questionnaire-
based study had not told their doctor about their use of CAM
(22). These data highlight the importance of communication in
children with IBD who may be using CAM agents.
A recent Canadian report developed a series of specific ques-
tions that could be ways to start a conversation about CAM during
a consultation (31). One sample question was “What else do you
do to support your child’s health?” The authors also outlined a
series of specific points to cover during these discussions. The use
of these approaches should help to enhance communication about
CAM in children with IBD.
Ensuring clear lines of communication about the use of CAM
agents is important in regards to safety of these interventions
(32). Herbal remedies, for instance, have been associated with
hepatic and renal impairment. However, there are not yet clear
data on adverse events related to the use of CAM in children
with IBD.
SUMMARY AND CONCLUSION
Overall, CAM agents are commonly administered to children with
IBD. The available reports indicate that at least 40% of such
children have recently been given CAM, with a smaller number
currently using. The usage rates and the types of CAM agents
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administered differ between the reported studies, with variations
within and between countries.
These differences may reflect methodological differences, with
different questionnaires or approaches to collection of data. Stan-
dardization of questionnaires and the adoption of consistent
methods more would ensure more direct comparison within and
between regions or countries. Even if such standard approach was
adopted, it is likely that variation between countries would per-
sist, reflecting different cultural attitudes to CAM and different
patterns of access to various CAM agents.
Furthermore, the available studies highlight differences in the
factors reported to influence CAM usage between European and
North American cohorts. Again these variations may reflect access
to particular CAM agents.
Some data indicates that children with IBD use CAM more
frequently than healthy children (2, 4). It is unclear if this is
a reflection of the chronic and incurable nature of IBD, or
the specific involvement of the GI tract (and consequent bowel
symptoms). In addition, increasing rates of CAM usage in chil-
dren with IBD may reflect changes and attitudes in the wider
community.
Probiotics and fish oil are two widely used agents in children
with IBD. This may reflect the wider exposure of information
about these agents consequent to numerous scientific reports. Even
though the data to universally support these therapies is lacking,
the fact that these have been subject to scientific scrutiny may
have enhanced their profile. Other agents with less awareness or
exposure may be utilized less as a consequence.
In conclusion, CAM agents are used frequently by children and
adolescents with IBD in almost every reported study. It is likely that
rates will continue to increase. Pediatric gastroenterologists caring
for children with IBD must ensure adequate personal understand-
ing and awareness of CAM agents, and have a working knowledge
of potential roles, possible interactions, and contraindications.
Furthermore, pediatric gastroenterologists must remember to ask
patients and parents about their use of CAM.
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